from Wiktionary, Creative Commons Attribution/Share-Alike License

  • n. A monoclonal antibody directed against the complement protein C5.


from Wiktionary, Creative Commons Attribution/Share-Alike License

-li- +‎ -zu- +‎ -mab


  • Food and Drug Administration cleared the medicine Soliris, chemically known as eculizumab, for atypical hemolytic uremic syndrome on the condition the company conducts additional clinical trials to confirm the medicine's benefit, the Cheshire, Connecticut-based company said in a statement.

  • Soliris, generically known as eculizumab, is the first approved treatment for aHUS.

    Reuters: Press Release

  • Shares of Alexion Pharmaceuticals rose 31% last week after the Cheshire, Conn.-based company reported positive late-stage results for eculizumab, an experimental anemia drug.

    Drug Approvals, Earnings Energize Drug Stocks

  • What carries the load for Alexion Pharma is its flagship drug Soliris eculizumab.

  • The post goes on to say: "Alexion stressed in its filing that eculizumab is not approved for the treatment of STEC-HUS in Germany or elsewhere ... the drug maker said it is supplying Soliris at no charge to physicians who request it for STEC-HUS patients."

  • Alexion Treating Europe's E Coli Victims, notes: "Alexion reports Tuesday in its 8-K filing to the Securities and Exchange Commission that its German subsidiary has been deluged with physician requests for eculizumab - branded as Soliris - to treat patients suffering from Shiga-toxin producing E. coli hemolytic uremic syndrome STEC-HUS."

  • Soliris eculizumab is not approved for the treatment of aHUS or any indication other than PNH.

  • ("Alexion", or the "Company") reported net product sales of Soliris ® (eculizumab) of $156.0 million, reflecting strong additions of new patients, compared to $110.6 million for the same period in 2009.

  • Soliris® eculizumab, Alexion's first marketed product, is approved in more than 35 countries as a therapy for patients with PNH, a debilitating and ultra-rare life-threatening blood disorder.

  • During the fourth quarter of 2010, Alexion made significant progress on advancing the development of eculizumab as a treatment for patients suffering from additional rare and severe complement-mediated disorders beyond PNH, with a focus on its two lead nephrology programs in aHUS and transplant.


Log in or sign up to get involved in the conversation. It's quick and easy.